APO Research
Talk to an analyst

APO RESEARCH · REPORT

Platinum-based Anticancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Platinum-based Anticancer Drugs Market Outlook and Growth Opportunities 2026

20 December 2025205 pages

Choose your research edition.

Industry ResearchPlatinum-based Anticancer Drugs Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Platinum-based Anticancer Drugs Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Platinum-based Anticancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Platinum-based Anticancer Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Platinum-based Anticancer Drugs Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Platinum-based Anticancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Platinum-based Anticancer Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Platinum-based Anticancer Drugs market include Teva, Sun Pharmaceutical, Qilu Pharmaceutical, Nanjing Pharmaceutical Factory, Mylan, Luoxin, Jiangsu Aosaikang Pharmaceutical, Jiangsu Hengrui Medicine and Fresenius Kabi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Platinum-based Anticancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Platinum-based Anticancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Platinum-based Anticancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Platinum-based Anticancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Platinum-based Anticancer Drugs Segment by Company

Teva

Sun Pharmaceutical

Qilu Pharmaceutical

Nanjing Pharmaceutical Factory

Mylan

Luoxin

Jiangsu Aosaikang Pharmaceutical

Jiangsu Hengrui Medicine

Fresenius Kabi

Yakult honsha

Taj Pharmaceuticals

Sanofi-Aventis

Lingnan Pharmacy

Hospira(Pfizer)

Hisun Pharmaceutical

Hansoh Pharma

Dr Reddy's laboratories

Platinum-based Anticancer Drugs Segment by Type

Oxaliplatin

Carboplatin

Nedaplatin

Cisplatin

Others

Platinum-based Anticancer Drugs Segment by Application

Esophageal Cancer

Breast Cancer

Osteosarcoma

Testicular Cancer

NSCLC

Other

Platinum-based Anticancer Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Platinum-based Anticancer Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Platinum-based Anticancer Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Platinum-based Anticancer Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Platinum-based Anticancer Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum-based Anticancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Platinum-based Anticancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum-based Anticancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Platinum-based Anticancer Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Platinum-based Anticancer Drugs industry.

Chapter 3: Detailed analysis of Platinum-based Anticancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Platinum-based Anticancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Platinum-based Anticancer Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Platinum-based Anticancer Drugs Industry Trends Table 2. Platinum-based Anticancer Drugs Industry Drivers Table 3. Platinum-based Anticancer Drugs Industry Opportunities and Challenges Table 4. Platinum-based Anticancer Drugs Industry Restraints Table 5. Global Platinum-based Anticancer Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Platinum-based Anticancer Drugs Revenue Share by Company (2021-2026) Table 7. Global Platinum-based Anticancer Drugs Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Platinum-based Anticancer Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Platinum-based Anticancer Drugs Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Platinum-based Anticancer Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Platinum-based Anticancer Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Platinum-based Anticancer Drugs Company, Product Type & Application Table 13. Global Platinum-based Anticancer Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Platinum-based Anticancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oxaliplatin Table 18. Significant Companies of Carboplatin Table 19. Significant Companies of Nedaplatin Table 20. Significant Companies of Cisplatin Table 21. Significant Companies of Others Table 22. Global Platinum-based Anticancer Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 23. Global Platinum-based Anticancer Drugs Sales Volume by Type (2021-2026) & (Tons) Table 24. Global Platinum-based Anticancer Drugs Sales Volume by Type (2027-2032) & (Tons) Table 25. Global Platinum-based Anticancer Drugs Sales Volume Share by Type (2021-2026) Table 26. Global Platinum-based Anticancer Drugs Sales Volume Share by Type (2027-2032) Table 27. Global Platinum-based Anticancer Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Platinum-based Anticancer Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Platinum-based Anticancer Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Platinum-based Anticancer Drugs Sales Value Share by Type (2021-2026) Table 31. Global Platinum-based Anticancer Drugs Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Esophageal Cancer Table 33. Significant Companies of Breast Cancer Table 34. Significant Companies of Osteosarcoma Table 35. Significant Companies of Testicular Cancer Table 36. Significant Companies of NSCLC Table 37. Significant Companies of Other Table 38. Global Platinum-based Anticancer Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 39. Global Platinum-based Anticancer Drugs Sales Volume by Application (2021-2026) & (Tons) Table 40. Global Platinum-based Anticancer Drugs Sales Volume by Application (2027-2032) & (Tons) Table 41. Global Platinum-based Anticancer Drugs Sales Volume Share by Application (2021-2026) Table 42. Global Platinum-based Anticancer Drugs Sales Volume Share by Application (2027-2032) Table 43. Global Platinum-based Anticancer Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Platinum-based Anticancer Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Platinum-based Anticancer Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Platinum-based Anticancer Drugs Sales Value Share by Application (2021-2026) Table 47. Global Platinum-based Anticancer Drugs Sales Value Share by Application (2027-2032) Table 48. Global Platinum-based Anticancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 49. Global Platinum-based Anticancer Drugs Sales by Region (2021-2026) & (Tons) Table 50. Global Platinum-based Anticancer Drugs Sales Market Share by Region (2021-2026) Table 51. Global Platinum-based Anticancer Drugs Sales by Region (2027-2032) & (Tons) Table 52. Global Platinum-based Anticancer Drugs Sales Market Share by Region (2027-2032) Table 53. Global Platinum-based Anticancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Platinum-based Anticancer Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Platinum-based Anticancer Drugs Sales Value Share by Region (2021-2026) Table 56. Global Platinum-based Anticancer Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Platinum-based Anticancer Drugs Sales Value Share by Region (2027-2032) Table 58. Global Platinum-based Anticancer Drugs Market Average Price (US$/Ton) by Region (2021-2026) Table 59. Global Platinum-based Anticancer Drugs Market Average Price (US$/Ton) by Region (2027-2032) Table 60. Global Platinum-based Anticancer Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 61. Global Platinum-based Anticancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Platinum-based Anticancer Drugs Sales by Country (2021-2026) & (Tons) Table 63. Global Platinum-based Anticancer Drugs Sales Market Share by Country (2021-2026) Table 64. Global Platinum-based Anticancer Drugs Sales by Country (2027-2032) & (Tons) Table 65. Global Platinum-based Anticancer Drugs Sales Market Share by Country (2027-2032) Table 66. Global Platinum-based Anticancer Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Platinum-based Anticancer Drugs Sales Value Market Share by Country (2021-2026) Table 68. Global Platinum-based Anticancer Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Platinum-based Anticancer Drugs Sales Value Market Share by Country (2027-2032) Table 70. Teva Company Information Table 71. Teva Business Overview Table 72. Teva Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 73. Teva Platinum-based Anticancer Drugs Product Portfolio Table 74. Teva Recent Development Table 75. Sun Pharmaceutical Company Information Table 76. Sun Pharmaceutical Business Overview Table 77. Sun Pharmaceutical Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 78. Sun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio Table 79. Sun Pharmaceutical Recent Development Table 80. Qilu Pharmaceutical Company Information Table 81. Qilu Pharmaceutical Business Overview Table 82. Qilu Pharmaceutical Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 83. Qilu Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio Table 84. Qilu Pharmaceutical Recent Development Table 85. Nanjing Pharmaceutical Factory Company Information Table 86. Nanjing Pharmaceutical Factory Business Overview Table 87. Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 88. Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Product Portfolio Table 89. Nanjing Pharmaceutical Factory Recent Development Table 90. Mylan Company Information Table 91. Mylan Business Overview Table 92. Mylan Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 93. Mylan Platinum-based Anticancer Drugs Product Portfolio Table 94. Mylan Recent Development Table 95. Luoxin Company Information Table 96. Luoxin Business Overview Table 97. Luoxin Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 98. Luoxin Platinum-based Anticancer Drugs Product Portfolio Table 99. Luoxin Recent Development Table 100. Jiangsu Aosaikang Pharmaceutical Company Information Table 101. Jiangsu Aosaikang Pharmaceutical Business Overview Table 102. Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 103. Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio Table 104. Jiangsu Aosaikang Pharmaceutical Recent Development Table 105. Jiangsu Hengrui Medicine Company Information Table 106. Jiangsu Hengrui Medicine Business Overview Table 107. Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 108. Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Product Portfolio Table 109. Jiangsu Hengrui Medicine Recent Development Table 110. Fresenius Kabi Company Information Table 111. Fresenius Kabi Business Overview Table 112. Fresenius Kabi Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 113. Fresenius Kabi Platinum-based Anticancer Drugs Product Portfolio Table 114. Fresenius Kabi Recent Development Table 115. Yakult honsha Company Information Table 116. Yakult honsha Business Overview Table 117. Yakult honsha Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 118. Yakult honsha Platinum-based Anticancer Drugs Product Portfolio Table 119. Yakult honsha Recent Development Table 120. Taj Pharmaceuticals Company Information Table 121. Taj Pharmaceuticals Business Overview Table 122. Taj Pharmaceuticals Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 123. Taj Pharmaceuticals Platinum-based Anticancer Drugs Product Portfolio Table 124. Taj Pharmaceuticals Recent Development Table 125. Sanofi-Aventis Company Information Table 126. Sanofi-Aventis Business Overview Table 127. Sanofi-Aventis Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 128. Sanofi-Aventis Platinum-based Anticancer Drugs Product Portfolio Table 129. Sanofi-Aventis Recent Development Table 130. Lingnan Pharmacy Company Information Table 131. Lingnan Pharmacy Business Overview Table 132. Lingnan Pharmacy Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 133. Lingnan Pharmacy Platinum-based Anticancer Drugs Product Portfolio Table 134. Lingnan Pharmacy Recent Development Table 135. Hospira(Pfizer) Company Information Table 136. Hospira(Pfizer) Business Overview Table 137. Hospira(Pfizer) Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 138. Hospira(Pfizer) Platinum-based Anticancer Drugs Product Portfolio Table 139. Hospira(Pfizer) Recent Development Table 140. Hisun Pharmaceutical Company Information Table 141. Hisun Pharmaceutical Business Overview Table 142. Hisun Pharmaceutical Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 143. Hisun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio Table 144. Hisun Pharmaceutical Recent Development Table 145. Hansoh Pharma Company Information Table 146. Hansoh Pharma Business Overview Table 147. Hansoh Pharma Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 148. Hansoh Pharma Platinum-based Anticancer Drugs Product Portfolio Table 149. Hansoh Pharma Recent Development Table 150. Dr Reddy's laboratories Company Information Table 151. Dr Reddy's laboratories Business Overview Table 152. Dr Reddy's laboratories Platinum-based Anticancer Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 153. Dr Reddy's laboratories Platinum-based Anticancer Drugs Product Portfolio Table 154. Dr Reddy's laboratories Recent Development Table 155. Key Raw Materials Table 156. Raw Materials Key Suppliers Table 157. Platinum-based Anticancer Drugs Distributors List Table 158. Platinum-based Anticancer Drugs Customers List Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Platinum-based Anticancer Drugs Product Image Figure 2. Global Platinum-based Anticancer Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Platinum-based Anticancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Platinum-based Anticancer Drugs Sales (2021-2032) & (Tons) Figure 5. Global Platinum-based Anticancer Drugs Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Platinum-based Anticancer Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oxaliplatin Image Figure 10. Carboplatin Image Figure 11. Nedaplatin Image Figure 12. Cisplatin Image Figure 13. Others Image Figure 14. Global Platinum-based Anticancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 15. Global Platinum-based Anticancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Platinum-based Anticancer Drugs Sales Volume Share by Type (2021-2032) Figure 17. Global Platinum-based Anticancer Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Platinum-based Anticancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Platinum-based Anticancer Drugs Sales Value Share by Type (2021-2032) Figure 20. Esophageal Cancer Image Figure 21. Breast Cancer Image Figure 22. Osteosarcoma Image Figure 23. Testicular Cancer Image Figure 24. NSCLC Image Figure 25. Other Image Figure 26. Global Platinum-based Anticancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 27. Global Platinum-based Anticancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Platinum-based Anticancer Drugs Sales Volume Share by Application (2021-2032) Figure 29. Global Platinum-based Anticancer Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Platinum-based Anticancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Platinum-based Anticancer Drugs Sales Value Share by Application (2021-2032) Figure 32. Global Platinum-based Anticancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 33. Global Platinum-based Anticancer Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Platinum-based Anticancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Platinum-based Anticancer Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Platinum-based Anticancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. North America Platinum-based Anticancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Platinum-based Anticancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Platinum-based Anticancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Platinum-based Anticancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Platinum-based Anticancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Platinum-based Anticancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. South America Platinum-based Anticancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Platinum-based Anticancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Platinum-based Anticancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Platinum-based Anticancer Drugs Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Platinum-based Anticancer Drugs Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • Oxaliplatin
  • Carboplatin
  • Nedaplatin
  • Cisplatin
  • Others
Applications
  • Esophageal Cancer
  • Breast Cancer
  • Osteosarcoma
  • Testicular Cancer
  • NSCLC
  • Other
Companies covered
  • Teva
  • Sun Pharmaceutical
  • Qilu Pharmaceutical
  • Nanjing Pharmaceutical Factory
  • Mylan
  • Luoxin
  • Jiangsu Aosaikang Pharmaceutical
  • Jiangsu Hengrui Medicine
  • Fresenius Kabi
  • Yakult honsha
  • Taj Pharmaceuticals
  • Sanofi-Aventis
  • Lingnan Pharmacy
  • Hospira(Pfizer)
  • Hisun Pharmaceutical
  • Hansoh Pharma
  • Dr Reddy's laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Platinum-based Anticancer Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Platinum-based Anticancer Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Platinum-based Anticancer Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Platinum-based Anticancer Drugs Market Dynamics
  1. 2.1 Platinum-based Anticancer Drugs Industry Trends
  2. 2.2 Platinum-based Anticancer Drugs Industry Drivers
  3. 2.3 Platinum-based Anticancer Drugs Industry Opportunities and Challenges
  4. 2.4 Platinum-based Anticancer Drugs Industry Restraints
3 Platinum-based Anticancer Drugs Market by Company
  1. 3.1 Global Platinum-based Anticancer Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Platinum-based Anticancer Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Platinum-based Anticancer Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Platinum-based Anticancer Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Platinum-based Anticancer Drugs Company Ranking (2024-2026)
  6. 3.6 Global Platinum-based Anticancer Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Platinum-based Anticancer Drugs Company Product Type and Application
  8. 3.8 Global Platinum-based Anticancer Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Platinum-based Anticancer Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Platinum-based Anticancer Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Platinum-based Anticancer Drugs Market by Type
  1. 4.1 Platinum-based Anticancer Drugs Type Introduction
  2. 4.1.1 Oxaliplatin
  3. 4.1.2 Carboplatin
  4. 4.1.3 Nedaplatin
  5. 4.1.4 Cisplatin
  6. 4.1.5 Others
  7. 4.2 Global Platinum-based Anticancer Drugs Sales Volume by Type
  8. 4.2.1 Global Platinum-based Anticancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Platinum-based Anticancer Drugs Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Platinum-based Anticancer Drugs Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Platinum-based Anticancer Drugs Sales Value by Type
  12. 4.3.1 Global Platinum-based Anticancer Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Platinum-based Anticancer Drugs Sales Value by Type (2021-2032)
  14. 4.3.3 Global Platinum-based Anticancer Drugs Sales Value Share by Type (2021-2032)
5 Platinum-based Anticancer Drugs Market by Application
  1. 5.1 Platinum-based Anticancer Drugs Application Introduction
  2. 5.1.1 Esophageal Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Osteosarcoma
  5. 5.1.4 Testicular Cancer
  6. 5.1.5 NSCLC
  7. 5.1.6 Other
  8. 5.2 Global Platinum-based Anticancer Drugs Sales Volume by Application
  9. 5.2.1 Global Platinum-based Anticancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Platinum-based Anticancer Drugs Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Platinum-based Anticancer Drugs Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Platinum-based Anticancer Drugs Sales Value by Application
  13. 5.3.1 Global Platinum-based Anticancer Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Platinum-based Anticancer Drugs Sales Value by Application (2021-2032)
  15. 5.3.3 Global Platinum-based Anticancer Drugs Sales Value Share by Application (2021-2032)
6 Platinum-based Anticancer Drugs Regional Sales and Value Analysis
  1. 6.1 Global Platinum-based Anticancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Platinum-based Anticancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Platinum-based Anticancer Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Platinum-based Anticancer Drugs Sales by Region (2027-2032)
  5. 6.3 Global Platinum-based Anticancer Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Platinum-based Anticancer Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Platinum-based Anticancer Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Platinum-based Anticancer Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Platinum-based Anticancer Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Platinum-based Anticancer Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Platinum-based Anticancer Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Platinum-based Anticancer Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Platinum-based Anticancer Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Platinum-based Anticancer Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Platinum-based Anticancer Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Platinum-based Anticancer Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Platinum-based Anticancer Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Platinum-based Anticancer Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Platinum-based Anticancer Drugs Sales Value Share by Country, 2025 VS 2032
7 Platinum-based Anticancer Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Platinum-based Anticancer Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Platinum-based Anticancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Platinum-based Anticancer Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Platinum-based Anticancer Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Platinum-based Anticancer Drugs Sales by Country (2027-2032)
  6. 7.4 Global Platinum-based Anticancer Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Platinum-based Anticancer Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Platinum-based Anticancer Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Platinum-based Anticancer Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Platinum-based Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Platinum-based Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Platinum-based Anticancer Drugs Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sun Pharmaceutical
  8. 8.2.1 Sun Pharmaceutical Company Information
  9. 8.2.2 Sun Pharmaceutical Business Overview
  10. 8.2.3 Sun Pharmaceutical Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Nanjing Pharmaceutical Factory
  20. 8.4.1 Nanjing Pharmaceutical Factory Company Information
  21. 8.4.2 Nanjing Pharmaceutical Factory Business Overview
  22. 8.4.3 Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Product Portfolio
  24. 8.4.5 Nanjing Pharmaceutical Factory Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Platinum-based Anticancer Drugs Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Luoxin
  32. 8.6.1 Luoxin Company Information
  33. 8.6.2 Luoxin Business Overview
  34. 8.6.3 Luoxin Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Luoxin Platinum-based Anticancer Drugs Product Portfolio
  36. 8.6.5 Luoxin Recent Developments
  37. 8.7 Jiangsu Aosaikang Pharmaceutical
  38. 8.7.1 Jiangsu Aosaikang Pharmaceutical Company Information
  39. 8.7.2 Jiangsu Aosaikang Pharmaceutical Business Overview
  40. 8.7.3 Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
  42. 8.7.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
  43. 8.8 Jiangsu Hengrui Medicine
  44. 8.8.1 Jiangsu Hengrui Medicine Company Information
  45. 8.8.2 Jiangsu Hengrui Medicine Business Overview
  46. 8.8.3 Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Product Portfolio
  48. 8.8.5 Jiangsu Hengrui Medicine Recent Developments
  49. 8.9 Fresenius Kabi
  50. 8.9.1 Fresenius Kabi Company Information
  51. 8.9.2 Fresenius Kabi Business Overview
  52. 8.9.3 Fresenius Kabi Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Fresenius Kabi Platinum-based Anticancer Drugs Product Portfolio
  54. 8.9.5 Fresenius Kabi Recent Developments
  55. 8.10 Yakult honsha
  56. 8.10.1 Yakult honsha Company Information
  57. 8.10.2 Yakult honsha Business Overview
  58. 8.10.3 Yakult honsha Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Yakult honsha Platinum-based Anticancer Drugs Product Portfolio
  60. 8.10.5 Yakult honsha Recent Developments
  61. 8.11 Taj Pharmaceuticals
  62. 8.11.1 Taj Pharmaceuticals Company Information
  63. 8.11.2 Taj Pharmaceuticals Business Overview
  64. 8.11.3 Taj Pharmaceuticals Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Taj Pharmaceuticals Platinum-based Anticancer Drugs Product Portfolio
  66. 8.11.5 Taj Pharmaceuticals Recent Developments
  67. 8.12 Sanofi-Aventis
  68. 8.12.1 Sanofi-Aventis Company Information
  69. 8.12.2 Sanofi-Aventis Business Overview
  70. 8.12.3 Sanofi-Aventis Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi-Aventis Platinum-based Anticancer Drugs Product Portfolio
  72. 8.12.5 Sanofi-Aventis Recent Developments
  73. 8.13 Lingnan Pharmacy
  74. 8.13.1 Lingnan Pharmacy Company Information
  75. 8.13.2 Lingnan Pharmacy Business Overview
  76. 8.13.3 Lingnan Pharmacy Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Lingnan Pharmacy Platinum-based Anticancer Drugs Product Portfolio
  78. 8.13.5 Lingnan Pharmacy Recent Developments
  79. 8.14 Hospira(Pfizer)
  80. 8.14.1 Hospira(Pfizer) Company Information
  81. 8.14.2 Hospira(Pfizer) Business Overview
  82. 8.14.3 Hospira(Pfizer) Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Hospira(Pfizer) Platinum-based Anticancer Drugs Product Portfolio
  84. 8.14.5 Hospira(Pfizer) Recent Developments
  85. 8.15 Hisun Pharmaceutical
  86. 8.15.1 Hisun Pharmaceutical Company Information
  87. 8.15.2 Hisun Pharmaceutical Business Overview
  88. 8.15.3 Hisun Pharmaceutical Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Hisun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
  90. 8.15.5 Hisun Pharmaceutical Recent Developments
  91. 8.16 Hansoh Pharma
  92. 8.16.1 Hansoh Pharma Company Information
  93. 8.16.2 Hansoh Pharma Business Overview
  94. 8.16.3 Hansoh Pharma Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Hansoh Pharma Platinum-based Anticancer Drugs Product Portfolio
  96. 8.16.5 Hansoh Pharma Recent Developments
  97. 8.17 Dr Reddy's laboratories
  98. 8.17.1 Dr Reddy's laboratories Company Information
  99. 8.17.2 Dr Reddy's laboratories Business Overview
  100. 8.17.3 Dr Reddy's laboratories Platinum-based Anticancer Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Dr Reddy's laboratories Platinum-based Anticancer Drugs Product Portfolio
  102. 8.17.5 Dr Reddy's laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Platinum-based Anticancer Drugs Value Chain Analysis
  2. 9.1.1 Platinum-based Anticancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Platinum-based Anticancer Drugs Sales Mode & Process
  6. 9.2 Platinum-based Anticancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Platinum-based Anticancer Drugs Distributors
  9. 9.2.3 Platinum-based Anticancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst